Published in Epilepsia on July 01, 2010
Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev (2010) 1.68
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Brain inflammation as a biomarker in epilepsy. Biomark Med (2011) 1.23
Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron (2013) 1.16
Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics (2014) 1.16
Interictal spikes, seizures and ictal cell death are not necessary for post-traumatic epileptogenesis in vitro. Neurobiol Dis (2011) 1.13
Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics (2014) 1.09
Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia (2012) 1.06
Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy. Epilepsia (2011) 1.01
Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. Future Neurol (2012) 0.95
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia (2012) 0.95
Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology (2012) 0.95
The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics (2014) 0.93
Issues related to development of antiepileptogenic therapies. Epilepsia (2013) 0.91
Electrophysiological biomarkers of epilepsy. Neurotherapeutics (2014) 0.90
Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives. Br J Pharmacol (2012) 0.86
Influence of aspirin on pilocarpine-induced epilepsy in mice. Korean J Physiol Pharmacol (2013) 0.83
A Peptide Uncoupling BDNF Receptor TrkB from Phospholipase Cγ1 Prevents Epilepsy Induced by Status Epilepticus. Neuron (2015) 0.81
Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem Neurosci (2014) 0.79
Dynamic expression patterns of ATF3 and p53 in the hippocampus of a pentylenetetrazole-induced kindling model. Mol Med Rep (2014) 0.78
Epilepsy related to traumatic brain injury. Neurotherapeutics (2014) 0.77
Traumatic Brain Injury Causes a Tacrolimus-Sensitive Increase in Non-Convulsive Seizures in a Rat Model of Post-Traumatic Epilepsy. Int J Neurol Brain Disord (2014) 0.77
Posttraumatic Epilepsy: What's Contusion Got to Do With It? Epilepsy Curr (2012) 0.76
Impact of the neural cell adhesion molecule-derived peptide FGL on seizure progression and cellular alterations in the mouse kindling model. ACS Chem Neurosci (2014) 0.75
Role of adenosine signaling on pentylenetetrazole-induced seizures in zebrafish. Zebrafish (2015) 0.75
Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy. Sci Rep (2017) 0.75
Antiepileptogenic and Neuroprotective Effects of Pergularia daemia on Pilocarpine Model of Epilepsy. Front Pharmacol (2017) 0.75
Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol (1972) 16.34
Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia (2005) 9.32
A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia (2001) 6.97
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia (2007) 4.33
The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci (2009) 3.80
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci (2006) 3.36
A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med (2008) 3.16
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Long-term prognosis of seizures with onset in childhood. N Engl J Med (1998) 2.74
Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J Neurosci (2009) 2.53
Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol (2002) 2.43
Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. J Neurosci (1998) 2.42
Seizures after stroke: a prospective multicenter study. Arch Neurol (2000) 2.18
Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia (2009) 1.98
A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats. Neuroscience (2006) 1.95
Preventing and treating posttraumatic seizures: the human experience. Epilepsia (2009) 1.88
Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech (2009) 1.87
Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis (2007) 1.86
Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J Neurosci (2009) 1.85
Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis (2008) 1.74
Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil (2003) 1.62
Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia (2008) 1.56
Cyclicity of spontaneous recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol (2007) 1.55
Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia (2007) 1.53
The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry (2004) 1.51
In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia (2007) 1.50
Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia (2007) 1.48
Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol (1998) 1.46
Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav (2008) 1.44
Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis (2006) 1.43
Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci (2007) 1.40
The neurobehavioural comorbidities of epilepsy: can a natural history be developed? Lancet Neurol (2008) 1.38
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics (2009) 1.36
Posttraumatic epilepsy after controlled cortical impact injury in mice. Exp Neurol (2008) 1.34
Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res (2007) 1.29
Epileptogenesis in experimental models. Epilepsia (2007) 1.29
From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia (2009) 1.27
Epilepsy after head injury: an overview. Epilepsia (2009) 1.25
Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J Cereb Blood Flow Metab (2006) 1.23
Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol (2009) 1.22
Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci U S A (2009) 1.18
Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res (2004) 1.17
The NINDS epilepsy research benchmarks. Epilepsia (2009) 1.15
Mechanisms of epilepsy progression: current theories and perspectives from neuroplasticity in adulthood and development. Epilepsy Res (2004) 1.15
A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res (2000) 1.14
The pathogenic and progressive features of chronic human hippocampal epilepsy. Epilepsy Res (1996) 1.13
Quantitative diffusion MRI of hippocampus as a surrogate marker for post-traumatic epileptogenesis. Brain (2007) 1.12
Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev (2008) 1.11
Rapamycin: brain excitability studied in vitro. Epilepsia (2007) 1.09
mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J Biol Chem (2009) 1.08
An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology (2001) 1.06
Epileptogenesis-related genes revisited. Prog Brain Res (2006) 1.04
Complications associated with genetic background effects in models of experimental epilepsy. Prog Brain Res (2002) 1.04
Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist. CNS Drug Rev (2005) 1.02
Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res (2009) 1.01
Regulation and role of REST and REST4 variants in modulation of gene expression in in vivo and in vitro in epilepsy models. Neurobiol Dis (2006) 1.01
Genetic background regulates semaphorin gene expression and epileptogenesis in mouse brain after kainic acid status epilepticus. Neuroscience (2005) 1.01
Differences in sensitivity to the convulsant pilocarpine in substrains and sublines of C57BL/6 mice. Genes Brain Behav (2009) 1.01
Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res (2009) 1.00
Atipamezole, an alpha(2)-adrenoceptor antagonist, has disease modifying effects on epileptogenesis in rats. Epilepsy Res (2004) 1.00
A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia (2005) 1.00
Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. Brain Res (1995) 0.98
Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol (2007) 0.95
From laboratory to clinic: noradrenergic enhancement of physical therapy for stroke or trauma patients. Adv Neurol (1997) 0.94
A microarray study of gene and protein regulation in human and rat brain following middle cerebral artery occlusion. BMC Neurosci (2007) 0.94
The impact of genetic background on neurodegeneration and behavior in seizured mice. Genes Brain Behav (2004) 0.93
Differential gene expression in hippocampus following experimental brain trauma reveals distinct features of moderate and severe injuries. J Neurotrauma (2004) 0.93
Quantitative T2 mapping as a potential marker for the initial assessment of the severity of damage after traumatic brain injury in rat. Exp Neurol (2009) 0.93
Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia (2005) 0.89
Strain differences affect the induction of status epilepticus and seizure-induced morphological changes. Eur J Neurosci (2004) 0.89
Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neurosci Lett (2008) 0.89
Antiepileptic drugs in neuroprotection. Expert Opin Pharmacother (2004) 0.86
Prognosis of chronic and newly diagnosed epilepsy: revisiting temporal aspects. Curr Opin Neurol (2007) 0.85
Variation in Galr1 expression determines susceptibility to exocitotoxin-induced cell death in mice. Genes Brain Behav (2008) 0.84
Pilocarpine-induced seizures revisited: what does the model mimic? Epilepsy Curr (2009) 0.83
Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des (2004) 0.82
Differentially altered cerebral metabolism in ischemic rats by alpha2-adrenoceptor blockade and its relation to improved limb-placing reactions. Neuropharmacology (2002) 0.79
Kindling-related changes in afterdischarge "thresholds". Epilepsia (1976) 0.79